Early neonatal hydrocortisone: Study rather than treat

Pediatrics

Volumn 118, Issue 6, 2006, Pages 2540-2542

  Hallman, Mikko ^a   Peltoniemi, Outi ^a   Saarela, Timo ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; DOBUTAMINE; DOPAMINE; HYDROCORTISONE; MINERALOCORTICOID; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN;

CEREBRAL PALSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; HEMODYNAMICS; HIGH RISK INFANT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; INFECTION; NEUROLOGIC DISEASE; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STOMACH HEMORRHAGE; AGE; ARTICLE; LUNG DYSPLASIA; NEWBORN;

AGE FACTORS; BRONCHOPULMONARY DYSPLASIA; CLINICAL TRIALS; HUMANS; HYDROCORTISONE; INFANT, NEWBORN;

EID: 33947148620     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-2250     Document Type: Note

References (14)

1. Baden M, Bauer CR, Colle E, Klein G, Taeusch HW Jr, Stern L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics. 1972;50:526-534
2. Watterberg KL, Gerdes JS, Gifford KL, Lin HM. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics. 1999;104:1258-1263
3. Ng PC, Lee CH, Bnur FL, et al. A double-blind, randomized, controlled study of a "stress dose" of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. Pediatrics. 2006;117:367-375
4. Seri I. Hydrocortisone and vasopressor-resistant shock in pre-term neonates. Pediatrics. 2006;117:516-518
5. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. N Engl J Med. 2005;353:1711-1723
6. Peltoniemi O, Kari MA, Heinonen K, et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. J Pediatr. 2005;146:632-637
7. Peltoniemi O, Kari MA, Heinonen K, et al. Early low-dose hydrocortisone may stabilize the cardio-pulmonary status of VLBW infants during the first week. J Matern Fetal Neonatal Med. 2005;16(suppl 1):64
8. Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics. 2004;114:1649-1657
9. Bell EF, Strauss RG, Widness JA, et al. Randomized trial of liberal versus restrictive guidelines for red blood cell transfusion in preterm infants. Pediatrics. 2005;115:1685-1691
10. Bourbon J, Boucherat O, Chailley-Heu B, Delacourt C. Control mechanisms of lung alveolar development and their disorders in bronchopulmonary dysplasia. Pediatr Res. 2005;57:38R-46R
11. Watterberg KL; the PROPHET Study Group. Long term outcomes of extremely low birth weight infants treated with early low-dose hydrocortisone (HC) to prevent bronchopulmonary dysplasia (BPD). E-PAS. 2006:59:2755.4.
12. Lodygensky GA, Rademaker K, Zimine S, et al. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics. 2005;116:1-7
13. Finer NN, Powers RJ, Ou CH, et al. Prospective evaluation of postnatal steroid administration: a 1-year experience from the California Perinatal Quality Care Collaborative. Pediatrics. 2006;117:704-713
14. Kostadinova RM, Nawrocki AR, Frey FJ, Frey BM. Tumor necrosis factor alpha and phorbol 12-myristate-13-acetate down-regulate human 11beta-hydroxysteroid dehydrogenase type 2 through p50/p50 NF-kappaB homodimers and Egr-1. FASEB J. 2005;19:650-652